PellePharm
PrivateLast Round
Series C
Nov 20, 2018
Total Funding Raised
$94.5M
Company Overview
PellePharm is a biotechnology company that develops precision medicine therapies for rare dermatological conditions, including Gorlin Syndrome and Basal Cell Carcinomas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PellePharm Comparables
Compare PellePharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DermBiont | 86% | |
| Sol-Gel Technologies Ltd. | 83% | |
| Inhibitor Therapeutics, Inc. | 81% | |
PellePharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 20, 2018 | ||||
| Series B | Jul 31, 2017 | ||||
| Series A | Jul 1, 2015 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 31, 2017
$20M round led by BridgeBio Pharma
PellePharm Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PellePharm's valuation, stock price, and market status.